Bliss GVS Pharma (506197) Q4 09/10 earnings summary

Executive summary

• FY10 total income was Rs.17,113.16 lakh and PAT was Rs.4,172.16 lakh; net sales reached Rs.16,887.53 lakh.

• Directors recommended a 50% dividend, equal to Rs.0.50 per Rs.1 share, with total payout of Rs.603.35 lakh including dividend tax.

• The 25-year operating milestone coincided with plans for a second Palghar plant and a new Andheri corporate office.

Financial highlights

• Total income rose to Rs.17,113.16 lakh from Rs.13,987.76 lakh; net sales were Rs.16,887.53 lakh versus Rs.13,295.57 lakh.

• PBT was Rs.4,575.52 lakh versus Rs.4,025.35 lakh; PAT was Rs.4,172.16 lakh versus Rs.3,745.12 lakh.

• Total expenditure was Rs.12,537.63 lakh versus Rs.9,962.41 lakh; raw-material and packing-material costs increased to Rs.9,136.45 lakh from Rs.6,968.42 lakh.

• Net cash from operating activities was Rs.689.61 lakh versus Rs.1,831.35 lakh; cash and bank balances closed at Rs.1,532.22 lakh versus Rs.684.89 lakh.

Outlook and guidance

• Plans included acquiring 6,000 sq. ft. in Andheri for a corporate office and expanding at Palghar, Thane, with an additional second plant.